BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...

Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) stock tumbled 49.9% in premarket trading Thursday after investors expressed disappointment with preliminary data from the company’s experimental ...

Shares of Pyxis Oncology dropped after the pharmaceutical company said data from its trials on a treatment for a form of head and neck cancer showed a high incidence of adverse effects. The stock fell ...

Seattle and San Francisco scale back harm reduction policies distributing drug supplies, signaling a shift in how West Coast ...

SINGAPORE - Media OutReach Newswire - 22 December 2025 - Pyxis, a leading Singapore-based maritime electrification startup, has secured S$13 million in the first close of its S$18 million growth ...

Specialty drugs surpass pharma sales, reaching 52% of U.S. pharmaceutical sales in 2024, driven by immunology and oncology therapies.

St. Luke’s playbook building future pharmacy model details automation and AI strategies to enhance patient access and speed in Idaho health system.

A west Belfast woman who was described by a judge as a ‘patsy’ in a drugs supply operation today (Tuesday) avoided immediate custody. Judge Neil Rafferty KC imposed an 18 month sentence suspended for ...